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Introduction:  A retrospective  preliminary  study  assessed  the  feasibility  of  sentinel  lymph  node  biopsy
(SLNB)  in  the  management  of Merkel  cell  carcinoma  (MCC)  of  the  head  and  neck.
Patients  and  methods:  Twelve  patients  with  stage  I or II head  and  neck  MCC  underwent  SLNB  over a  4-year
period.
Results:  Only  1 of  the  12 patients  had  a positive  SLNB.  The sentinel  node  was  not  identiﬁed  in  3 patients.
Two of the  8  patients  with negative  SLNB  showed  regional  lymph  node  recurrence  within  2 years.  One
patient  died  during  follow-up.
Conclusion:  Merkel  cell  carcinoma  is  an  uncommon  but highly  aggressive  pathology;  management  pro-
tocols  have  been  based  on  small  series.  The  role  of SLNB  in  the management  of MCC  remains  to  be
deﬁned.
©  2015  Elsevier  Masson  SAS.  All  rights  reserved.. Introduction
Merkel cell carcinoma (MCC) is a rare and exceptionally aggres-
ive cutaneous neuroendocrine tumor, ﬁrst described by Toker
n 1972 [1]. Incidence is increasing, having tripled over the last
0 years [2]. It is a pathology of the elderly, most patients being
ged 65 years or over at diagnosis [3]. In decreasing order of fre-
uency, it involves the head and neck region, upper limbs, lower
imbs and trunk [4]; within the head and neck region, perioral and
eriocular locations are the most frequent.
Pathogenesis remains obscure. Suggested risk factors are ultra-
iolet radiation and immunodepression. Viral etiology has been
uggested since the discovery of a new polyomavirus by Feng et al.
n 2008 [5].
Several chromosome abnormalities have been recurrently asso-
iated with MCC: a deletion in the short arms of chromosome 1,
bnormal expression of tumor-suppressor gene Rb1 and L-Myc, a
DGFR- mutation, and bcl-2 overexpression [6].
Presentation is usually in the form of an isolated painless ﬁrm
urplish nodule in photo-exposed body areas. At diagnosis, regional
ymph node involvement is found in 25% of cases, and the lymph
ode drainage area is also the main site of recurrence [7]. Several
linical and histological prognostic factors have been assessed, but
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879-7296/© 2015 Elsevier Masson SAS. All rights reserved.lymph node involvement appears to be the major predictive factor
for survival [8].
Sentinel lymph node biopsy (SLNB), introduced in the 1990s
and of proven efﬁcacy in staging breast cancers and melanomas,
has been applied in MCC  to identify candidates for complementary
treatment [9,10].
The present study reports a retrospective series of 12 patients
who underwent SLNB in the management of facial MCC in our
department.
2. Material and method
Twelve patients underwent SLNB in our department between
February 2008 and February 2012. Most had been referred for surgi-
cal revision following MCC  resection or biopsy. Tumor stages were
I or II. Extension assessment systematically comprised full clinical
examination, ultrasound examination of the lymph node drainage
area and thoracic-abdominal-pelvic CT scan. None of the patients
included showed lymph node or remote metastasis.
All cases were discussed in multidisciplinary team meetings.
SLNB was  performed in the same step as surgical revision of the
resection margins, which involved either 2-cm margins using con-
ventional pathology analysis or 1-cm margins using the Slow Mohs
technique [11]. Admission was on the day before surgery, with
technetium 99 injection in the Bordeaux University Hospital Center
nuclear medicine department, either on the eve or in the morning
of surgery.
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Table  1
Data for the 12 patients.
Patient Gender Age
(years)
MCC  location SLN status Neck dissection Recurrence FU
(mo)
Status
1 M 81 Right temple Negative 0 0 66 RFS
2  M 82 Forehead Negative 0 Lymph node 57
3  M 81 Forehead 0 0 0 56 RFS
4  F 65 Left cheek 0 0 0 53 RFS
5  F 73 Right cheek 0 0 0 34 RFS
6  F 87 Forehead Negative 0 Visceral 34 Deceased
7  F 75 Left cheek Negative 0 Lymph node 34 RFS
8  F 67 Right cheek Negative 0 0 36 RFS
9  F 65 Right eyebrow 0 0 Lymph node 57 RFS
10  F 86 Upper lip Positive 7 LNMs 0 31 RFS
11  M 75 Lower lip Negative 0 0 14 RFS
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Surgery was performed under general anesthesia. Lymph node
pecimens were sent for pathologic analysis.
When a lymph node showed micrometastasis, functional
esection of the drainage area was performed in a second step.
Postoperative complementary 50 Gy radiation therapy (RT) was
ystematically applied to the tumor site and drainage area in case
f positive SLNB or of certain risk factors: large tumor volume or
mmunodepression.
. Results
There were 4 male and 8 female patients, with a mean age of
4 years (range, 62–85 years).
Table 1 shows patient data.
SLNB was performed in the same step as surgical resection in 8
ases; in the other 4, resection had already been performed and the
atient had been referred for revision of insufﬁcient margins. The
ean interval between biopsy and surgical revision with SLNB was
6 days (range, 21–54 days).
Resection margins were 2 cm in 11 cases, with conventional
athology analysis, and 1 cm in 1 case, with Slow Mohs analysis.
The sentinel node could not be identiﬁed in 3 cases. One of these
resented parotid recurrence 4 months after SLNB and the other
 had undergone resection with insufﬁcient margins more than
 month previously. The mean number of sentinel nodes identiﬁed
n the other patients was 1.3 (range, 1–2).
SLNB was positive in only 1 patient, in whom neck dissection
evealed 7 invaded lymph nodes.
In 62.5% of cases (5 patients), the sentinel node was located in
he parotid. One patient with intraparotid sentinel node refused
issection due to the risk of facial nerve lesion.
The sentinel node was ipsilateral to the lesion in 7 out of 8 cases;
he other case concerned a medial lesion with 2 sentinel nodes
ocated on the right.
Eleven patients received 50 Gy postoperative RT of the tumor
ed and 3 received 50 Gy RT of the lymph node areas.
Four patients showed recurrence: 3 parotid, and 1 with vis-
eral metastases. Mean interval to recurrence after surgery was
0 months (range, 4–15 months). The case of recurrence at 4
onths was in a patient in whom lymphoscintigraphy was  negativeor sentinel nodes (Fig. 1).
SLNB was false negative in 1 patient.
Eleven patients were in recurrence-free survival at the time of
riting, and 1 had died from related causes.0 0 12 RFS
 node metastasis; RFS: recurrence-free survival.
Mean survival was 40 months (range, 12–66 months).
4. Discussion
MCC  is a rare form of skin cancer at high risk of local and lymph
node recurrence. Mortality is higher than for melanoma, with 5-
year survival ranging from 30% to 64% [7,12]. Optimal management
remains to be deﬁned, as the rarity of the pathology means there
are no randomized trials in the literature.
The high rate of lymph node recurrence associated with MCC,
due to its lymphophilic character and the presence of micro-
scopic lymph node metastases in 29–32% of patients at diagnosis,
has stimulated the search for prophylactic treatments against
lymph node recurrence. Prophylactic neck dissection and selective
adenectomy have not, however, demonstrated beneﬁt in overall or
recurrence-free survival [13].
Sentinel node biopsy, used in breast cancer and melanoma
assessment, has been applied in MCC  in recent years, with beneﬁt,
according to some reports, in terms of speciﬁc and overall survival
[9,13,14].
The present study analyzed a retrospective series of 12 patients
with facial MCC  in whom SLNB was  applied. In the literature, only
Schmalbach et al. [15] have similarly reported a series of 10 patients
with head and neck MCC  receiving SLNB. Other series have been
heterogeneous, assessing the technique in MCC  throughout the
body, without focus on the head and neck [9,10,16]. The absence of
head and neck series of MCC  is doubtless due to rarity, preventing
the recruitment of large series, and to the difﬁculty of sampling sen-
tinel nodes in the facial region. This difﬁculty principally resides in
risk to the facial nerve in case of intraparotid sentinel node, in the
possibility of multiple bilateral or contralateral sentinel nodes and
in the proximity of the injection site to the sentinel node. The last
of these difﬁculties can be resolved by resecting the lesion before
exploring for the sentinel node [17].
In 5 patients, the sentinel node was located in the parotid. One
patient refused resection due to the risk to the facial nerve, but
showed no recurrence at 53 months’ follow-up. In the other cases,
the sentinel node could be removed without superﬁcial parotidec-
tomy and without causing facial nerve lesion. Schmalbach et al.
reported no complications in parotid sentinel node resection in 5
patients [15].
One patient later showed parotid recurrence despite negative
SLNB; this was  the only false negative. The literature describes
the difﬁculty of intraparotid sentinel node resection, with false
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iig. 1. Lymphoscintigraphy and 3D CT scan locating sentinel lymph nodes. A. 99mT
axial,  sagittal and coronal). C. Fusion of CT and lymphoscintigraphic images.
egative rates higher than in other locations [18]. The density
f parotid tissue hampers location of small lymph nodes; some
uthors therefore recommend systematic superﬁcial parotidec-
omy for intraparotid sentinel nodes, although this attitude is
ot free of morbidity [17]. In the present series, lymphoscintig-
aphy identiﬁed no sentinel nodes in 3 patients (25%); 2 had
ndergone previous lesion resection by another surgeon leaving
nsufﬁcient margins, which interrupted lymph drainage and pre-
ented SLNB; the third showed parotid metastasis 4 months after
ymphoscintigraphy. Non-detection may  have been due to lymph
essel obstruction by MCC  metastasis cells, as described else-
here [19]. In the literature, non-detection rates range between
 and 35%, mainly in case of head and neck MCC  locations
9,16].
Only 1 of the 8 sentinel nodes removed was positive (12.5%),
hereas the literature reports lymph node metastasis in 19–48% of
ases [10,15]. However, 1 patient in whom the sentinel node was
ot identiﬁed presented micrometastases with parotid invasion
 months after lymphoscintigraphy. Three patients with negative
LNB showed recurrence (42.8%): two in the lymph nodes (28.5%),
lthough in an area other than that of the sentinel node, and 1
ith visceral metastases. The regional recurrence rate associated
ith negative SLNB ranges between 8% and 60%, depending on the
eport [15,16,20]; these differences are certainly due to differences
n lymph node area management from team to team, in the absencehoscintigraphy (axial, sagittal, coronal. “Droit”: right; “Gauche”: left). B. 3D CT scan
of consensus. A single patient was false negative (12.5%), a ﬁnding
comparable to those of Schmalbach et al. and Fields et al. [15,20].
At the time of writing, 9 patients (75%) were in more than
2 years’ recurrence-free survival. This is encouraging, as 90% of
recurrences occur within 2 years [9]. The present series, however,
was too small for a study of SLNB impact on recurrence-free or over-
all survival; literature data are also sparse and of poor quality, as
series have either been small or heterogeneous.
Gupta et al. reported a signiﬁcant correlation between
recurrence-free survival and sentinel node status [9]. Kubika [21],
in a multicenter study of 108 patients, reported signiﬁcant corre-
lation between recurrence-free survival and sentinel node status
given sufﬁcient follow-up.
Lemos et al. [14] found signiﬁcantly elevated 5-year survival in
case of negative sentinel node. Warner et al. [16], in a series includ-
ing 12 head and neck MCCs, reported a higher rate of recurrence
associated with positive versus negative sentinel node (18.7% vs.
7.5%).
SLNB has the further advantage of identifying the lymph node
drainage area associated with the lesion. In the head and neck
region, drainage is highly variable, with discrepancy between clin-
ical prediction and lymphoscintigraphy in one-third of cases, as
also reported in melanoma [22]. Lymphoscintigraphic determina-
tion of the drainage area can help target postoperative RT and neck
dissection.
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In the present series, 11 patients (91%) underwent postopera-
ive irradiation of the tumor site, 3 of whom (25%) also had lymph
ode area RT. According to several reports, RT applied to the tumor
ite and/or ﬁrst lymph node chain improves locoregional control
nd overall survival [23,24], although these were basically hetero-
eneous retrospective studies.
Jouary et al. [25], in a prospective study, reported that systematic
rradiation of the surgical site signiﬁcantly reduced the probabil-
ty of regional recurrence (PRR). In our center, complementary
rainage area RT in negative SLNB is discussed in a multidisciplinary
eam meeting according to tumoral criteria (size, thickness) and
mmune status. Lymph node area RT is performed systematically
fter neck dissection in case of positive SLNB.
Among the various teams performing SLNB in MCC, there is no
onsensus as to treatment strategy; postoperative RT is not system-
tic, even in case of sentinel node invasion [16]. Optimal treatment
or MCC  remains controversial. There is agreement on the need
or extensive tumor resection, but indications for RT and adjuvant
hemotherapy remain to be deﬁned.
. Conclusion
The present study reports a homogeneous series of patients
eceiving SLNB for head and neck MCC. The sample size was, how-
ver, too small to analyze the impact of the technique on overall
nd recurrence-free survival. Results demonstrated the reliability
f SLNB, despite the difﬁculties inherent to head and neck loca-
ions. Lymphoscintigraphy helps determine drainage area for RT,
ead and neck lymph node drainage being highly variable.
At present, the therapeutic contribution of SLNB remains to be
roven, as the rarity of head and neck MCC  precludes randomized
tudy.
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